News
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
UCB’s Fintepla has been approved to treat seizures associated with two epilepsy disorders and now has posted data that could ...
The medtech this week launched a podcast called “Decoded,” in which founder and CEO Jurgi Camblong, Ph.D., will host expert ...
Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain blood cancers—until now. | The FDA has removed the REMS requirements for ...
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions
For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...
Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established ...
Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...
The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...
Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company ...
After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results